Andes Biotechnologies

What Andes Biotechnologies does

Andes Biotechnologies is a privately held, preclinical-stage biotechnology company founded in 2008 and headquartered in Santiago, Chile. According to its firmographic profile, the company is focused on nucleic acid-based drug discovery and development for solid tumor cancers, operating with a small team of 11–50 employees and led by co-founders Pablo Valenzuela (CEO and President) and Luis Burzio (CSO and Head of Preclinical Research), with Cristian Hernandez-Cuevas as COO. The underlying technology platform centers on nucleic acid (oligonucleotide-based) modalities aimed at oncology targets in solid tumors, though specific programs, mechanisms, or candidate molecules are not disclosed in the available data.

The company's business model is consistent with a preclinical-stage biotech: it does not appear to commercialize approved products or generate product revenue, and its go-to-market is implicitly structured around advancing internal candidates toward clinical milestones that would attract licensing, partnership, or M&A interest from larger pharmaceutical counterparties. Pricing, customer, and channel information are not present in the source material. Between 2010 and 2014 Andes Biotechnologies raised capital across at least five funding rounds from Chilean investors Aurus and Austral Capital (with a Series 2 designation in 2010 and again in December 2014), suggesting a recurring relationship with a narrow set of domestic institutional backers rather than diversified international syndication.

The evidence base for this company is thin. Multiple aggregated source blocks contained content about unrelated entities (ALEXISTOGEL, Watsons Indonesia) rather than Andes Biotechnologies, and there is no disclosed information on clinical pipeline stage, IP portfolio, partnerships, regulatory filings, or post-2014 capital activity. Investors evaluating the asset should treat the public profile as a founder-led, Chile-based preclinical nucleic acid biotech with limited recent disclosed activity.

Name

Andes Biotechnologies

Website

https://andesbio.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

11–50 employees

Short description

Andes Biotechnologies is a privately held, preclinical-stage Chilean biotechnology company founded in 2008 that develops nucleic acid-based therapeutics for solid tumor cancers, operating with 11–50 employees under co-founders Pablo Valenzuela (CEO) and Luis Burzio (CSO).

Ownership category

akta.pro rank

Product category

Oncology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL)

akta.pro secondary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Nucleic acid therapeutics
• Cancer drug discovery
• Solid tumor therapeutics
• Antisense oligonucleotide research
• Oncology drug development

Headquarters

HQ city

Santiago

HQ country

Chile

HQ region

Latin America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations

Distribution channels2 records

Marketing channels5 records

Core offering

Andes Biotechnologies is a drug discovery and development company focused on creating nucleic acid-based therapeutics for solid tumor cancers. The company leverages antisense oligonucleotide technology to identify and develop novel oncology drug candidates, operating as a preclinical-to-early-clinical-stage biotechnology company headquartered in Santiago, Chile.

Product overview

No product information for Andes Biotechnologies found in the provided source content. The source data pertains to ALEXISTOGEL, a lottery/gambling website providing Toto Macau 4D result services, and Watsons, a retail/healthcare chain. Neither company is Andes Biotechnologies.

Differentiator

Problem solved

Functional benefit

Products and services

• Nucleic Acid-Based Oncology Therapeutics Pipeline

Quantifiable outcome

• Transaction processing within approximately 1 minute

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators1 record

Recent moves5 records

Expansion highlights2 records

Direct peers

• Alnylam Pharmaceuticals: Leading clinical-stage company developing RNA interference (siRNA) therapeutics, with several approved drugs and an active oncology pipeline. Closely comparable to Andes in modality (nucleic-acid-based drugs) and therapeutic ambition, though at vastly larger scale and later stage.
• Wave Life Sciences: Clinical-stage genetic medicines company developing nucleic-acid therapeutics (including stereopure oligonucleotides) with oncology and rare disease programs. Similar modality and early-stage development profile to Andes.
• Arrowhead Pharmaceuticals: Clinical-stage siRNA therapeutics company with oncology programs among its pipeline. Comparable to Andes in nucleic-acid modality and oncology focus, but with deeper resources and partnered programs.
• Ionis Pharmaceuticals: Pioneer in antisense oligonucleotide (ASO) drug discovery and development, with a broad pipeline including oncology programs. Directly comparable to Andes as a nucleic-acid-based drug discovery company targeting serious diseases, including cancer.
• Regulus Therapeutics: Clinical-stage company developing microRNA-targeted therapeutics, with historical oncology programs. Comparable to Andes in the nucleic-acid-based drug discovery space targeting oncology indications.

Broad incumbents

• Moderna: Large commercial-stage mRNA therapeutics company with a significant oncology pipeline. A broader incumbent operating at much greater scale, but directly overlapping with Andes in the nucleic-acid-based therapeutic modality for cancer.
• BioNTech: Commercial-stage mRNA therapeutics company with multiple oncology programs and approved immuno-oncology assets. A broadly comparable peer in nucleic-acid-based cancer therapeutics, though at vastly greater scale and clinical maturity.

Emerging players

• MiNA Therapeutics: Clinical-stage company developing RNA activation (RNAa) therapeutics for cancer and other diseases. Comparable to Andes in nucleic-acid-based drug discovery and oncology focus, at a slightly more advanced stage.
• Silence Therapeutics: Clinical-stage company developing siRNA therapeutics, including oncology programs. Comparable to Andes in nucleic-acid modality and oncology focus, but at a more advanced clinical stage.

Regional players

• PharmaMar: Spanish-headquartered oncology-focused biopharmaceutical company with approved marine-derived cancer therapeutics and a pipeline of additional oncology candidates. Comparable to Andes as an oncology-focused biotech headquartered outside the major US/EU biotech hubs, with a focus on differentiated cancer therapeutics.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/andes-biotechnologies-s-a-

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds5 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Andes Biotechnologies